Loading...
Header Logo
Keywords
Last Name
Institution

JOE Y CHANG

TitleProfessor
InstitutionMD Anderson
DepartmentRadiation Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Moreno AC, Fellman B, Hobbs BP, Liao Z, Gomez DR, Chen A, Hahn SM, Chang JY, Lin SH. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 Aug 31. PMID: 31479748.
      View in: PubMed
    2. Verma V, Ludmir EB, Mesko SM, Brooks ED, Augustyn A, Milano MT, Lin SH, Chang JY, Welsh JW. Commercial Insurance Coverage of Advanced Radiotherapy Techniques Compared to American Society for Radiation Oncology Model Policies. Pract Radiat Oncol. 2019 Aug 22. PMID: 31446147.
      View in: PubMed
    3. Brooks ED, Verma V, Chang JY. Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC? Front Oncol. 2019; 9:551. PMID: 31293978.
      View in: PubMed
    4. Li H, Verma V, Brooks ED, Feng L, Zhang T, Welsh JW, Lin SH, Gomez D, Gandhi S, Heymach JV, Chang JY. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. Clin Lung Cancer. 2019 Jul; 20(4):e480-e488. PMID: 31078421.
      View in: PubMed
    5. Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, Atalar C, Selek U, Chun SG, Chang JY, Barsoumian HB, Nguyen QN, Altan M, Cortez MA, Hahn SM, Welsh JW. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol. 2019; 10:193. PMID: 30828330.
      View in: PubMed
    6. Zhuang H, Shi S, Yuan Z, Chang JY. Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. Mol Cancer. 2019 02 07; 18(1):21. PMID: 30732625.
      View in: PubMed
    7. Verma V, Haque W, Cushman TR, Lin C, Simone CB, Chang JY, McClelland S, Welsh JW. Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. J Immunother. 2019 Feb/Mar; 42(2):55-64. PMID: 30628924.
      View in: PubMed
    8. Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol. 2019 02; 16(2):123-135. PMID: 30401936.
      View in: PubMed
    9. Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019 Apr 01; 103(5):1077-1084. PMID: 30513377.
      View in: PubMed
    10. Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, Thomas CR. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018 11 23; 6(1):128. PMID: 30470252.
      View in: PubMed
    11. Vassiliev ON, Kry SF, Wang HC, Peterson CB, Chang JY, Mohan R. Radiotherapy of lung cancers: FFF beams improve dose coverage at tumor periphery compromised by electronic disequilibrium. Phys Med Biol. 2018 09 28; 63(19):195007. PMID: 30189421.
      View in: PubMed
    12. Verma V, Chang JY. Dose-escalation of locally advanced non-small cell lung cancer with proton beam therapy. Transl Lung Cancer Res. 2018 Sep; 7(Suppl 3):S280-S282. PMID: 30393622.
      View in: PubMed
    13. Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, Liao Z, Jeter M, O'Reilly M, Welsh JW, Nguyen QN, Erasmus JJ, Eapen G, Ahrar K, Antonoff MB, Hahn SM, Heymach JV, Rice DC, Chang JY. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open. 2018 08 03; 1(4):e181390. PMID: 30646121.
      View in: PubMed
    14. Chang JY. In Reply to Hurmuz and Ozyigit. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):745. PMID: 29893286.
      View in: PubMed
    15. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 07; 16(7):807-821. PMID: 30006423.
      View in: PubMed
    16. Li H, Chang JY. Accounting for, Mitigating, and Choice of Margins for Moving Tumors. Semin Radiat Oncol. 2018 06; 28(3):194-200. PMID: 29933879.
      View in: PubMed
    17. Zhang Y, Shen J, Simone CB, Cappuzzo F, Fong KM, Rosell R, Chang JY, Ampollini L, Choi JI, He J, Jiang T. How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. J Thorac Dis. 2018 Jun; 10(6):3883-3890. PMID: 30069390.
      View in: PubMed
    18. Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, Li A, Younes AI, Cadena A, Cushman TR, Chang JY, Nguyen QN, Gomez DR, Diab A, Heymach JV, Hwu P, Cortez MA, Welsh JW. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. Clin Cancer Res. 2018 Nov 15; 24(22):5735-5743. PMID: 29784675.
      View in: PubMed
    19. Verma V, Chang JY. Controversies in dose-escalation for locally advanced non-small cell lung cancer and the role of proton beam therapy. J Thorac Dis. 2018 Apr; 10(Suppl 9):S1124-S1126. PMID: 29849206.
      View in: PubMed
    20. Gomez DR, Li H, Chang JY. Proton therapy for early-stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2018 Apr; 7(2):199-204. PMID: 29876319.
      View in: PubMed
    21. Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, Jeter M, Nguyen QN, Li H, Zhang X, Poenisch F, Zhu XR, Balter PA, Feng L, Choi NC, Mohan R, Chang JY. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):558-563. PMID: 29680255.
      View in: PubMed
    22. Liu C, Schild SE, Chang JY, Liao Z, Korte S, Shen J, Ding X, Hu Y, Kang Y, Keole SR, Sio TT, Wong WW, Sahoo N, Bues M, Liu W. Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):479-489. PMID: 29550033.
      View in: PubMed
    23. Cushman TR, Gomez D, Kumar R, Likacheva A, Chang JY, Cadena AP, Paris S, Welsh JW. Combining radiation plus immunotherapy to improve systemic immune response. J Thorac Dis. 2018 Feb; 10(Suppl 3):S468-S479. PMID: 29593892.
      View in: PubMed
    24. Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep. 2018 01 31; 8(1):1922. PMID: 29386574.
      View in: PubMed
    25. Kang J, Chang JY, Sun X, Men Y, Zeng H, Hui Z. Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients. J Cancer. 2018; 9(3):584-593. PMID: 29483964.
      View in: PubMed
    26. Verma V, Chang JY. Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. J Thorac Dis. 2018 Jan; 10(1):21-24. PMID: 29600013.
      View in: PubMed
    27. de Groot PM, Shroff GS, Ahrar J, Sabloff BS, Gladish GM, Moran C, Gupta S, Gladish GW, Chang JY, Erasmus JJ. Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant. Adv Radiat Oncol. 2018 Apr-Jun; 3(2):139-145. PMID: 29904738.
      View in: PubMed
    28. Yu W, Tang C, Hobbs BP, Li X, Koay EJ, Wistuba II, Sepesi B, Behrens C, Rodriguez Canales J, Parra Cuentas ER, Erasmus JJ, Court LE, Chang JY. Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1090-1097. PMID: 29246722.
      View in: PubMed
    29. Pezzi TA, Tang C, Swanick CW, Fang P, Hess K, Xu T, Hahn SM, Chang JY, Liao Z, Gomez D. Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiother Oncol. 2017 11; 125(2):325-330. PMID: 29054376.
      View in: PubMed
    30. Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JD. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032. PMID: 28727865.
      View in: PubMed
    31. Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, Zhu XR, Gomez D, Lin SH, Gillin M, Komaki R, Hahn S, Chang JY. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):58-65. PMID: 28867546.
      View in: PubMed
    32. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676. PMID: 29280461.
      View in: PubMed
    33. Chang JY, Zhang X, Knopf A, Li H, Mori S, Dong L, Lu HM, Liu W, Badiyan SN, Both S, Meijers A, Lin L, Flampouri S, Li Z, Umegaki K, Simone CB, Zhu XR. Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys. 2017 09 01; 99(1):41-50. PMID: 28816159.
      View in: PubMed
    34. Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039. PMID: 28346656.
      View in: PubMed
    35. Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, Balter PA, Welsh JD, O'Reilly M, Gomez D, Hahn SM, Sepesi B, Rice DC, Heymach JV, Chang JY. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol. 2017 06; 12(6):983-992. PMID: 28259750.
      View in: PubMed
    36. Chang JY, Zhang W, Komaki R, Choi NC, Chan S, Gomez D, O'Reilly M, Jeter M, Gillin M, Zhu X, Zhang X, Mohan R, Swisher S, Hahn S, Cox JD. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol. 2017 02; 122(2):274-280. PMID: 28139305.
      View in: PubMed
    37. Vial MR, Khan KA, O'Connell O, Peng SA, Gomez DR, Chang JY, Rice DC, Mehran R, Jimenez CJ, Grosu HB, Ost DE, Eapen GA. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients. Ann Thorac Surg. 2017 May; 103(5):1600-1605. PMID: 28027732.
      View in: PubMed
    38. Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Heymach JV, Rice DC, Chang JY. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):900-907. PMID: 28258887.
      View in: PubMed
    39. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27713162.
      View in: PubMed
    40. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850. PMID: 27821490.
      View in: PubMed
    41. Tang C, Chang JY. PD-L1 expression in lung cancer. J Thorac Dis. 2016 Nov; 8(11):3053-3055. PMID: 28066581.
      View in: PubMed
    42. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382. PMID: 27794500.
      View in: PubMed
    43. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396. PMID: 27649551.
      View in: PubMed
    44. Chance WW, Nguyen QN, Mehran R, Welsh JW, Gomez DR, Balter P, Komaki R, Liao Z, Chang JY. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 2017 May - Jun; 7(3):e195-e203. PMID: 27743801.
      View in: PubMed
    45. Zhuang H, Yuan X, Chang JY, Song Y, Wang J, Yuan Z, Wang X, Wang P. Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation. Oncotarget. 2016 07 26; 7(30):48842-48849. PMID: 26934327.
      View in: PubMed
    46. Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J. 2016 Jul-Aug; 22(4):257-66. PMID: 27441745.
      View in: PubMed
    47. Selek U, Chang JY. Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer. J Thorac Dis. 2016 Jul; 8(7):1394-7. PMID: 27500390.
      View in: PubMed
    48. Swanick CW, Allen PK, Tao R, Olanrewaju AM, Sutton JR, Lin SH, Welsh J, Das P, Chang JY, Crane CH, Gomez DR. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):63-71. PMID: 27637136.
      View in: PubMed
    49. Zhuang H, Yuan X, Zheng Y, Li X, Chang JY, Wang J, Wang X, Yuan Z, Wang P. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Sci Rep. 2016 Apr 12; 6:24364. PMID: 27067388.
      View in: PubMed
    50. Moghanaki D, Chang JY. Is surgery still the optimal treatment for stage I non-small cell lung cancer? Transl Lung Cancer Res. 2016 Apr; 5(2):183-9. PMID: 27183993.
      View in: PubMed
    51. Khader J, Al-Mousa A, Hijla FA, Al-Heet S, Rashdan I, Balter P, Chang J, Wadi-Ramahi S. Requirements and Implementation of a Lung SBRT Program in a Developing Country: Benefits of International Cooperation. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1236-8. PMID: 27354130.
      View in: PubMed
    52. Li R, Pu X, Chang JY, Ye Y, Komaki R, Minna JD, Roth JA, Han B, Wu X. MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer. PLoS One. 2016; 11(3):e0150467. PMID: 26991123.
      View in: PubMed
    53. Zhao L, Zhou S, Balter P, Shen C, Gomez DR, Welsh JD, Lin SH, Chang JY. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1226-35. PMID: 27209498.
      View in: PubMed
    54. Zhuang H, Yuan X, Sun D, Bian J, Chang JY, Yuan Z, Wang P. Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report. Oncotarget. 2016 Mar 15; 7(11):13265-13268. PMID: 26933810.
      View in: PubMed
    55. Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016 08; 13(8):516-24. PMID: 26951040.
      View in: PubMed
    56. Yu J, Zhang X, Liao L, Li H, Zhu R, Park PC, Sahoo N, Gillin M, Li Y, Chang JY, Komaki R, Lin SH. Motion-robust intensity-modulated proton therapy for distal esophageal cancer. Med Phys. 2016 Mar; 43(3):1111-8. PMID: 26936698.
      View in: PubMed
    57. Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J. 2016 Mar-Apr; 22(2):130-7. PMID: 27111909.
      View in: PubMed
    58. Videtic GM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, Schild SE, Komaki R, Urbanic JJ, Choy H. Erratum. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):638. PMID: 26867895.
      View in: PubMed
    59. Zhao L, Pu X, Ye Y, Lu C, Chang JY, Wu X. Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer. Cancers (Basel). 2016 Feb 18; 8(2). PMID: 26901225.
      View in: PubMed
    60. Zhuang H, Zheng Y, Wang J, Chang JY, Wang X, Yuan Z, Wang P. Analysis of risk and predictors of brain radiation necrosis after radiosurgery. Oncotarget. 2016 Feb 16; 7(7):7773-9. PMID: 26675376.
      View in: PubMed
    61. Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8. PMID: 26891607.
      View in: PubMed
    62. Xu JY, Lu S, Xu XY, Hu SL, Li B, Li WX, Chang JY. Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs. Tumour Biol. 2016 Aug; 37(8):10349-56. PMID: 26846099.
      View in: PubMed
    63. Chang JY, Senan S, Smit EF, Roth JA. Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' reply. Lancet Oncol. 2016 Feb; 17(2):e42-e43. PMID: 26868349.
      View in: PubMed
    64. Chang JY, Jabbour SK, De Ruysscher D, Schild SE, Simone CB, Rengan R, Feigenberg S, Khan AJ, Choi NC, Bradley JD, Zhu XR, Lomax AJ, Hoppe BS. Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):505-16. PMID: 27084663.
      View in: PubMed
    65. Prabhakar R, Oates R, Daryl J, Chang J, Geso M, Cramb J. Rectal complication probability from composite volumes derived from daily cone beam computed tomography in prostate cancer radiotherapy. J Cancer Res Ther. 2016 Jan-Mar; 12(1):374-8. PMID: 27072266.
      View in: PubMed
    66. Cortez MA, Valdecanas D, Niknam S, Peltier HJ, Diao L, Giri U, Komaki R, Calin GA, Gomez DR, Chang JY, Heymach JV, Bader AG, Welsh JW. In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. Mol Ther Nucleic Acids. 2015 Dec 15; 4:e270. PMID: 26670277.
      View in: PubMed
    67. Liu W, Schild SE, Chang JY, Liao Z, Chang YH, Wen Z, Shen J, Stoker JB, Ding X, Hu Y, Sahoo N, Herman MG, Vargas C, Keole S, Wong W, Bues M. Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):523-33. PMID: 26725727.
      View in: PubMed
    68. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980. PMID: 26310908.
      View in: PubMed
    69. Chang JY, Senan S, Smit EF, Roth JA. Surgery versus SABR for resectable non-small-cell lung cancer - Authors' reply. Lancet Oncol. 2015 Aug; 16(8):e374-5. PMID: 26248841.
      View in: PubMed
    70. Videtic GM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, Schild SE, Komaki R, Urbanic JJ, Timmerman RD, Choy H. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):757-64. PMID: 26530743.
      View in: PubMed
    71. Smith BD, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Shirvani SM. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol. 2015 Jul; 6(4):324-31. PMID: 26094172.
      View in: PubMed
    72. Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, Allen PK, Mehran RJ, Lu C, Gillin M, Liao Z, Cox JD. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015 Jun; 115(3):367-72. PMID: 26028228.
      View in: PubMed
    73. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015 Jun; 16(6):630-7. PMID: 25981812.
      View in: PubMed
    74. Willers H, Stinchcombe TE, Barriger RB, Chetty IJ, Ginsburg ME, Kestin LL, Kumar S, Loo BW, Movsas B, Rimner A, Rosenzweig KE, Videtic GM, Chang JY. ACR Appropriateness Criteria(®) induction and adjuvant therapy for N2 non-small-cell lung cancer. Am J Clin Oncol. 2015 Apr; 38(2):197-205. PMID: 25803563.
      View in: PubMed
    75. Chang JY, Bezjak A, Mornex F. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. J Thorac Oncol. 2015 Apr; 10(4):577-85. PMID: 25514807.
      View in: PubMed
    76. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015 Jun; 41(6):503-10. PMID: 25872878.
      View in: PubMed
    77. Grant JD, Shirvani SM, Tang C, Juloori A, Rebueno NC, Allen PK, Chang JY. Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer. Pract Radiat Oncol. 2015 Jul-Aug; 5(4):e383-91. PMID: 25731965.
      View in: PubMed
    78. Li H, Zhang X, Park P, Liu W, Chang J, Liao Z, Frank S, Li Y, Poenisch F, Mohan R, Gillin M, Zhu R. Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiother Oncol. 2015 Mar; 114(3):367-72. PMID: 25708992.
      View in: PubMed
    79. Xu JY, Lu S, Xu XY, Hu SL, Li B, Qi RX, Chen L, Chang JY. Knocking Down Nucleolin Expression Enhances the Radiosensitivity of Non-Small Cell Lung Cancer by Influencing DNA-PKcs Activity. Asian Pac J Cancer Prev. 2015; 16(8):3301-6. PMID: 25921135.
      View in: PubMed
    80. Chang JY. Stereotactic ablative radiotherapy: aim for a cure of cancer. Ann Transl Med. 2015 Jan; 3(1):12. PMID: 25705644.
      View in: PubMed
    81. Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Smith BD. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg. 2014 Dec; 149(12):1244-53. PMID: 25321323.
      View in: PubMed
    82. Chang JY. Intensity-modulated radiotherapy, not 3 dimensional conformal, is the preferred technique for treating locally advanced lung cancer. Semin Radiat Oncol. 2015 Apr; 25(2):110-6. PMID: 25771415.
      View in: PubMed
    83. Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DR. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):149-56. PMID: 25442335.
      View in: PubMed
    84. Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer. 2015 Mar; 16(2):156-63. PMID: 25467928.
      View in: PubMed
    85. Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, Pan HY, Chang JY, Komaki R, Cox JD, McAleer MF, Grosshans DR. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014 Oct; 9(10):1554-60. PMID: 25521400.
      View in: PubMed
    86. Chang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, Li Y, Sahoo N, Poenisch F, Gomez DR, Wu R, Gillin M, Zhang X. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):809-18. PMID: 25260491.
      View in: PubMed
    87. McAvoy S, Ciura K, Wei C, Rineer J, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):819-27. PMID: 25220718.
      View in: PubMed
    88. Li H, Liu W, Park P, Matney J, Liao Z, Chang J, Zhang X, Li Y, Zhu RX. Evaluation of the systematic error in using 3D dose calculation in scanning beam proton therapy for lung cancer. J Appl Clin Med Phys. 2014 Sep 08; 15(5):4810. PMID: 25207565.
      View in: PubMed
    89. He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol. 2014 Sep; 9(9):1398-405. PMID: 25122435.
      View in: PubMed
    90. De Ruysscher D, Pijls-Johannesma M, Chang JY, Langendijk JA. The cost of setting up and operating a hadron facility. In regard to Vanderstraeten et al. Int J Radiat Oncol Biol Phys. 2014 Sep 01; 90(1):238. PMID: 25195995.
      View in: PubMed
    91. Chang JY, Kestin LL, Barriger RB, Chetty IJ, Ginsburg ME, Kumar S, Loo BW, Movsas B, Rimner A, Rosenzweig KE, Stinchcombe TE, Videtic GM, Willers H. ACR Appropriateness Criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. Oncology (Williston Park). 2014 Aug 15; 28(8):706-10, 712, 714 passim. PMID: 25140629.
      View in: PubMed
    92. Kardar L, Li Y, Li X, Li H, Cao W, Chang JY, Liao L, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e259-68. PMID: 25407877.
      View in: PubMed
    93. Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, Balter PA, Chang JY. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol. 2014 Aug; 112(2):256-61. PMID: 25108807.
      View in: PubMed
    94. Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clin Pharmacol Ther. 2014 Nov; 96(5):609-15. PMID: 25054431.
      View in: PubMed
    95. Grant JD, Chang JY. Proton-based stereotactic ablative radiotherapy in early-stage non-small-cell lung cancer. Biomed Res Int. 2014; 2014:389048. PMID: 25136582.
      View in: PubMed
    96. Chang JY. In reply to Oskan. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1142. PMID: 25035223.
      View in: PubMed
    97. Zhuang H, Yuan Z, Chang JY, Wang J, Pang Q, Zhao L, Wang P. Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J Thorac Oncol. 2014 Jun; 9(6):882-5. PMID: 24828665.
      View in: PubMed
    98. Zhuang H, Zhao X, Zhao L, Chang JY, Wang P. Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer. Drug Des Devel Ther. 2014; 8:667-75. PMID: 24936128.
      View in: PubMed
    99. Zhu Z, Liu W, Gillin M, Gomez DR, Komaki R, Cox JD, Mohan R, Chang JY. Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial. Radiat Oncol. 2014 May 06; 9:108. PMID: 24886059.
      View in: PubMed
    100. Videtic GM, Chang JY, Chetty IJ, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Loo BW, Movsas B, Stinchcombe TE, Willers H, Rosenzweig KE. ACR appropriateness Criteria® early-stage non-small-cell lung cancer. Am J Clin Oncol. 2014 Apr; 37(2):201-7. PMID: 25180631.
      View in: PubMed
    101. Gomez DR, Chang JY. Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. J Thorac Dis. 2014 Apr; 6(4):348-55. PMID: 24688779.
      View in: PubMed
    102. Chang JY, De Ruysscher D. Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer. J Thorac Dis. 2014 Apr; 6(4):285-6. PMID: 24688773.
      View in: PubMed
    103. Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, Balter P, Komaki R, Mehran R, Swisher SG, Roth JA. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1120-8. PMID: 24661665.
      View in: PubMed
    104. Sanchez-Espiridion B, Chen M, Chang JY, Lu C, Chang DW, Roth JA, Wu X, Gu J. Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. Cancer Res. 2014 May 01; 74(9):2476-86. PMID: 24618342.
      View in: PubMed
    105. Li Y, Kardar L, Li X, Li H, Cao W, Chang JY, Liao L, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys. 2014 Feb; 41(2):021721. PMID: 24506612.
      View in: PubMed
    106. Zhang X, Lin SH, Fang B, Gillin M, Mohan R, Chang JY. Therapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol. 2013 Dec; 8(12):1484-91. PMID: 24389430.
      View in: PubMed
    107. Gomez DR, Poenisch F, Pinnix CC, Sheu T, Chang JY, Memon N, Mohan R, Rozner MA, Dougherty AH. Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors. Int J Radiat Oncol Biol Phys. 2013 Nov 01; 87(3):570-5. PMID: 24074931.
      View in: PubMed
    108. McAvoy SA, Ciura KT, Rineer JM, Allen PK, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013 Oct; 109(1):38-44. PMID: 24016675.
      View in: PubMed
    109. Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, Banchs J, Komaki R, Welsh JW. Cardiac ¹8F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol. 2013 Oct; 109(1):82-8. PMID: 24016676.
      View in: PubMed
    110. Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):139-47. PMID: 23920393.
      View in: PubMed
    111. Chang JY. Oncology scan--promising strategies for the treatment of locally-advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):1-4. PMID: 23920382.
      View in: PubMed
    112. Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA, Smith BD. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer. 2013 Nov; 82(2):252-9. PMID: 24018022.
      View in: PubMed
    113. Shirvani SM, Chang JY, Roth JA. Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery? Thorac Surg Clin. 2013 Aug; 23(3):369-81. PMID: 23931020.
      View in: PubMed
    114. Rosenzweig KE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Langer CJ, Movsas B, Videtic GM, Willers H. ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. J Am Coll Radiol. 2013 Sep; 10(9):654-64. PMID: 23890874.
      View in: PubMed
    115. Hou DL, Shi GF, Gao XS, Asaumi J, Li XY, Liu H, Yao C, Chang JY. Improved longitudinal length accuracy of gross tumor volume delineation with diffusion weighted magnetic resonance imaging for esophageal squamous cell carcinoma. Radiat Oncol. 2013 Jul 06; 8:169. PMID: 23829638.
      View in: PubMed
    116. Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, Roth JA, Swisher SG. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013 Sep 15; 119(18):3402-10. PMID: 23798353.
      View in: PubMed
    117. Pan T, Riegel AC, Ahmad MU, Sun X, Chang JY, Luo D. New weighted maximum-intensity-projection images from cine CT for delineation of the lung tumor plus motion. Med Phys. 2013 Jun; 40(6):061901. PMID: 23718592.
      View in: PubMed
    118. Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA, Hsiung CA, Yang P. Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Res. 2013 Jul 01; 73(13):4028-38. PMID: 23704207.
      View in: PubMed
    119. Gomez DR, Gillin M, Liao Z, Wei C, Lin SH, Swanick C, Alvarado T, Komaki R, Cox JD, Chang JY. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):665-70. PMID: 23688815.
      View in: PubMed
    120. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014 Feb-Mar; 27(2):168-75. PMID: 23621168.
      View in: PubMed
    121. De Ruysscher D, Chang JY. Clinical controversies: proton therapy for thoracic tumors. Semin Radiat Oncol. 2013 Apr; 23(2):115-9. PMID: 23473688.
      View in: PubMed
    122. Kong FM, Lally BE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Langer CJ, Movsas B, Videtic GM, Willers H, Rosenzweig KE. ACR Appropriateness Criteria® radiation therapy for small-cell lung cancer. Am J Clin Oncol. 2013 Apr; 36(2):206-13. PMID: 23511336.
      View in: PubMed
    123. Niibe Y, Chang JY, Onishi H, Salama J, Hiraki T, Yamashita H. Oligometastases/Oligo-recurrence of lung cancer. Pulm Med. 2013; 2013:438236. PMID: 23476762.
      View in: PubMed
    124. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902. PMID: 23341526.
      View in: PubMed
    125. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013 May; 24(5):1312-9. PMID: 23300016.
      View in: PubMed
    126. Welsh J, Amini A, Ciura K, Nguyen N, Palmer M, Allen PK, Paolini M, Liao Z, Bluett J, Mohan R, Gomez D, Cox JD, Komaki R, Chang JY. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim. 2013; 38(4):442-447. PMID: 24200220.
      View in: PubMed
    127. McAleer MF, Balter P, Bucci MK, Kuruvila S, Komaki R, Chang JY. Capsular contracture of subcutaneous breast implant following hypofractionated stereotactic body radiotherapy for early stage lung cancer. J Radiosurg SBRT. 2013; 2(2):165-170. PMID: 29296356.
      View in: PubMed
    128. Zhang X, Fang B, Mohan R, Chang JY. Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. Radiother Oncol. 2012 Nov; 105(2):250-7. PMID: 23022172.
      View in: PubMed
    129. Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1060-70. PMID: 22975611.
      View in: PubMed
    130. Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 2012 Sep 10; 7:152. PMID: 22963661.
      View in: PubMed
    131. Quan EM, Chang JY, Liao Z, Xia T, Yuan Z, Liu H, Li X, Wages CA, Mohan R, Zhang X. Automated volumetric modulated Arc therapy treatment planning for stage III lung cancer: how does it compare with intensity-modulated radio therapy? Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):e69-76. PMID: 22901421.
      View in: PubMed
    132. Xiang ZL, Erasmus J, Komaki R, Cox JD, Chang JY. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiat Oncol. 2012 Aug 28; 7:144. PMID: 22929048.
      View in: PubMed
    133. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3. PMID: 22921233.
      View in: PubMed
    134. Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med. 2012; 2012:261096. PMID: 22966429.
      View in: PubMed
    135. Gomez DR, Niibe Y, Chang JY. Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. Pulm Med. 2012; 2012:396592. PMID: 22900169.
      View in: PubMed
    136. Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA, Lin SH. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20. PMID: 22819472.
      View in: PubMed
    137. Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1558-65. PMID: 22572078.
      View in: PubMed
    138. Shirvani SM, Chang JY. Proton therapy for non-small cell lung cancer: Current evidence and future directions. Thorac Cancer. 2012 May; 3(2):99-108. PMID: 28920298.
      View in: PubMed
    139. Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1017-23. PMID: 22543216.
      View in: PubMed
    140. Koay EJ, Lege D, Mohan R, Komaki R, Cox JD, Chang JY. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1093-100. PMID: 22543217.
      View in: PubMed
    141. Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol. 2011; 1:52. PMID: 22649768.
      View in: PubMed
    142. Decker RH, Langer CJ, Rosenzweig KE, Chang JY, Gewanter RM, Ginsburg ME, Kong FM, Lally BE, Videtic GM, Movsas B. ACR Appropriateness Criteria® postoperative adjuvant therapy in non-small cell lung cancer. Am J Clin Oncol. 2011 Oct; 34(5):537-44. PMID: 21946673.
      View in: PubMed
    143. Chang JY. Stereotactic ablative radiotherapy for stage I NSCLC: Successes and existing challenges. J Thorac Dis. 2011 Sep; 3(3):144-6. PMID: 22263079.
      View in: PubMed
    144. Shirvani SM, Chang JY. Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team. Cancers (Basel). 2011 Sep 01; 3(3):3432-48. PMID: 24212962.
      View in: PubMed
    145. Grosshans D, Boehling NS, Palmer M, Spicer C, Erice R, Cox JD, Komaki R, Chang JY. Improving cardiac dosimetry: Alternative beam arrangements for intensity modulated radiation therapy planning in patients with carcinoma of the distal esophagus. Pract Radiat Oncol. 2012 Jan-Mar; 2(1):41-5. PMID: 24674035.
      View in: PubMed
    146. Xiang ZL, Zeng ZC, Fan J, Tang ZY, He J, Zeng HY, Chang JY. The expression of HIF-1a in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol Biol Rep. 2012 Feb; 39(2):2021-9. PMID: 21647551.
      View in: PubMed
    147. Liu H, Chang JY. Proton therapy in clinical practice. Chin J Cancer. 2011 May; 30(5):315-26. PMID: 21527064.
      View in: PubMed
    148. Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):e91-7. PMID: 21489716.
      View in: PubMed
    149. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011 May 18; 103(10):817-25. PMID: 21483023.
      View in: PubMed
    150. Yu W, Fu XL, Zhang YJ, Xiang JQ, Shen L, Chang JY. A prospective evaluation of staging and target volume definition of lymph nodes by 18FDG PET/CT in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e759-65. PMID: 21470788.
      View in: PubMed
    151. Peng Y, Vedam S, Chang JY, Gao S, Sadagopan R, Bues M, Balter P. Implementation of feedback-guided voluntary breath-hold gating for cone beam CT-based stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Jul 01; 80(3):909-17. PMID: 21470784.
      View in: PubMed
    152. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011 Oct 15; 117(20):4707-13. PMID: 21437893.
      View in: PubMed
    153. Nguyen GH, Murph MM, Chang JY. Cancer stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers. Cancers (Basel). 2011 Mar; 3(1):1232-52. PMID: 21603589.
      View in: PubMed
    154. Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011 Jul 01; 117(13):3004-13. PMID: 21264827.
      View in: PubMed
    155. Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, Swisher SG, Gillin M, Mohan R, Cox JD. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1350-7. PMID: 21251767.
      View in: PubMed
    156. Loo BW, Chang JY, Dawson LA, Kavanagh BD, Koong AC, Senan S, Timmerman RD. Stereotactic ablative radiotherapy: what's in a name? Pract Radiat Oncol. 2011 Jan-Mar; 1(1):38-9. PMID: 24673868.
      View in: PubMed
    157. Lin SH, Chang JY. Esophageal cancer: diagnosis and management. Chin J Cancer. 2010 Oct; 29(10):843-54. PMID: 20868553.
      View in: PubMed
    158. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1. PMID: 20732513.
      View in: PubMed
    159. Gopal RS, Dubey S, Rosenzweig KE, Chang JY, Decker R, Gewanter RM, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):969-74. PMID: 20813465.
      View in: PubMed
    160. Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010 Aug 25; 5(8):e12402. PMID: 20811626.
      View in: PubMed
    161. Gomez DR, Chang JY. Adaptive radiation for lung cancer. J Oncol. 2011; 2011. PMID: 20814539.
      View in: PubMed
    162. Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 15; 80(4):1015-22. PMID: 20615629.
      View in: PubMed
    163. Chang JY, Cox JD. Improving radiation conformality in the treatment of non-small cell lung cancer. Semin Radiat Oncol. 2010 Jul; 20(3):171-7. PMID: 20652085.
      View in: PubMed
    164. Welsh J, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R, Chang JY. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):91-6. PMID: 20542388.
      View in: PubMed
    165. Gewanter RM, Rosenzweig KE, Chang JY, Decker R, Dubey S, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. Curr Probl Cancer. 2010 May-Jun; 34(3):228-49. PMID: 20541060.
      View in: PubMed
    166. Ikushima H, Balter P, Komaki R, Hunjun S, Bucci MK, Liao Z, McAleer MF, Yu ZH, Zhang Y, Chang JY, Dong L. Daily alignment results of in-room computed tomography-guided stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):473-80. PMID: 20399032.
      View in: PubMed
    167. Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, Chang JY. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1387-93. PMID: 20381271.
      View in: PubMed
    168. Nelson C, Balter P, Morice RC, Bucci K, Dong L, Tucker S, Vedam S, Chang JY, Starkschall G. Evaluation of tumor position and PTV margins using image guidance and respiratory gating. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1578-85. PMID: 20137865.
      View in: PubMed
    169. Liu SW, Li JM, Chang JY, Yu JM, Chen Q, Jiang QA, Mu XK, Zhao MH, Tian Y, Wei QL. A treatment planning comparison between proton beam therapy and intensity-modulated x-ray therapy for recurrent nasopharyngeal carcinoma. J Xray Sci Technol. 2010; 18(4):443-50. PMID: 21045280.
      View in: PubMed
    170. Yu W, Fu XL, Zhang YJ, Xiang JQ, Shen L, Jiang GL, Chang JY. GTV spatial conformity between different delineation methods by 18FDG PET/CT and pathology in esophageal cancer. Radiother Oncol. 2009 Dec; 93(3):441-6. PMID: 19682760.
      View in: PubMed
    171. Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox JD, Chang JY. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010 Jun 01; 77(2):357-66. PMID: 19660879.
      View in: PubMed
    172. McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? Cancer. 2009 Jul 15; 115(14):3233-42. PMID: 19472405.
      View in: PubMed
    173. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with esophageal cancer radiation therapy. J Thorac Oncol. 2009 Jul; 4(7):880-8. PMID: 19458557.
      View in: PubMed
    174. Gayed IW, Liu HH, Wei X, Liao Z, Yusuf SW, Chang JY, Bassett R, Komaki R. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol. 2009 Feb; 4(2):179-84. PMID: 19179893.
      View in: PubMed
    175. Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol. 2009 Jan 30; 4:5. PMID: 19183471.
      View in: PubMed
    176. Ezhil M, Vedam S, Balter P, Choi B, Mirkovic D, Starkschall G, Chang JY. Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography. Radiat Oncol. 2009 Jan 27; 4:4. PMID: 19173738.
      View in: PubMed
    177. Vassiliev ON, Kry SF, Chang JY, Balter PA, Titt U, Mohan R. Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. J Appl Clin Med Phys. 2009 Jan 27; 10(1):2880. PMID: 19223837.
      View in: PubMed
    178. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):967-71. PMID: 18954709.
      View in: PubMed
    179. Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, Gu J, Hong WK, Stewart D, Spitz MR. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics. 2008 Nov; 18(11):955-65. PMID: 18854777.
      View in: PubMed
    180. Nelson C, Balter P, Morice RC, Choi B, Kudchadker RJ, Bucci K, Chang JY, Dong L, Tucker S, Vedam S, Briere T, Starkschall G. A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials. J Appl Clin Med Phys. 2008 Oct 30; 9(4):2766. PMID: 19020478.
      View in: PubMed
    181. Britton KR, Starkschall G, Liu H, Chang JY, Bilton S, Ezhil M, John-Baptiste S, Kantor M, Cox JD, Komaki R, Mohan R. Consequences of anatomic changes and respiratory motion on radiation dose distributions in conformal radiotherapy for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):94-102. PMID: 18929448.
      View in: PubMed
    182. Gayed IW, Chang J, Kim EE, Nuñez R, Chasen B, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol. 2008 Aug; 3(8):858-64. PMID: 18670303.
      View in: PubMed
    183. Riegel AC, Chang JY, Vedam SS, Johnson V, Chi PC, Pan T. Cine computed tomography without respiratory surrogate in planning stereotactic radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):433-41. PMID: 18644683.
      View in: PubMed
    184. Hui Z, Zhang X, Starkschall G, Li Y, Mohan R, Komaki R, Cox JD, Chang JY. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys. 2008 Dec 01; 72(5):1385-95. PMID: 18486357.
      View in: PubMed
    185. Wagener M, Zhang X, Villarreal HG, Levy L, Allen P, Shentu S, Fang B, Krishnan S, Chang JY, Cheung MR. Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer. Oncol Rep. 2008 May; 19(5):1071-7. PMID: 18425360.
      View in: PubMed
    186. Zhang X, Komaki R, Wang L, Fang B, Chang JY. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res. 2008 May 01; 14(9):2813-23. PMID: 18451249.
      View in: PubMed
    187. Kennedy MP, Jimenez CA, Chang J, Fossella F, Eapen GA, Morice RC. Optimisation of bronchial brachytherapy catheter placement with a modified airway stent. Eur Respir J. 2008 Apr; 31(4):902-3. PMID: 18378785.
      View in: PubMed
    188. Chang JY, Dong L, Liu H, Starkschall G, Balter P, Mohan R, Liao Z, Cox JD, Komaki R. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):177-86. PMID: 18303441.
      View in: PubMed
    189. Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1409-16. PMID: 17904303.
      View in: PubMed
    190. Qiao XY, Wang W, Zhou ZG, Gao XS, Chang JY. Comparison of efficacy of regional and extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2008 Feb 01; 70(2):396-402. PMID: 17855004.
      View in: PubMed
    191. Zhu G, Cao X, Chang JY, Milas L, Wallace S, Li C. Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol Rep. 2007 Sep; 18(3):645-51. PMID: 17671714.
      View in: PubMed
    192. Chang JY, Roth JA. Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin. 2007 May; 17(2):251-9. PMID: 17626403.
      View in: PubMed
    193. Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF, Jeter MD, Correa A, Vaporciyan AA, Liu HH, Komaki R, Forster KM, Stevens CW. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):350-7. PMID: 17467922.
      View in: PubMed
    194. Shioyama Y, Jang SY, Liu HH, Guerrero T, Wang X, Gayed IW, Erwin WD, Liao Z, Chang JY, Jeter M, Yaremko BP, Borghero YO, Cox JD, Komaki R, Mohan R. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1349-58. PMID: 17446001.
      View in: PubMed
    195. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):779-85. PMID: 17418967.
      View in: PubMed
    196. Liu HH, Balter P, Tutt T, Choi B, Zhang J, Wang C, Chi M, Luo D, Pan T, Hunjan S, Starkschall G, Rosen I, Prado K, Liao Z, Chang J, Komaki R, Cox JD, Mohan R, Dong L. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys. 2007 Jun 01; 68(2):531-40. PMID: 17398035.
      View in: PubMed
    197. Britton KR, Starkschall G, Tucker SL, Pan T, Nelson C, Chang JY, Cox JD, Mohan R, Komaki R. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1036-46. PMID: 17379442.
      View in: PubMed
    198. Kang Y, Zhang X, Chang JY, Wang H, Wei X, Liao Z, Komaki R, Cox JD, Balter PA, Liu H, Zhu XR, Mohan R, Dong L. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):906-14. PMID: 17293240.
      View in: PubMed
    199. Nelson C, Starkschall G, Balter P, Morice RC, Stevens CW, Chang JY. Assessment of lung tumor motion and setup uncertainties using implanted fiducials. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):915-23. PMID: 17293241.
      View in: PubMed
    200. Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong Z, Wang X, Gao G, Wu TT, Komaki R, Chang JY. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):389-96. PMID: 17236963.
      View in: PubMed
    201. Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, Chang JY, Swafford J, Broemeling L, Liao Z. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med. 2006 Nov; 47(11):1756-62. PMID: 17079807.
      View in: PubMed
    202. Takahashi N, Yang DJ, Kohanim S, Oh CS, Yu DF, Azhdarinia A, Kurihara H, Zhang X, Chang JY, Kim EE. Targeted functional imaging of estrogen receptors with 99mTc-GAP-EDL. Eur J Nucl Med Mol Imaging. 2007 Mar; 34(3):354-62. PMID: 17021817.
      View in: PubMed
    203. Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol. 2006 Sep 20; 24(27):4485-91. PMID: 16983118.
      View in: PubMed
    204. Chang JY, Moughan J, Johnstone DW, Komaki R, Goldberg M, Langer CJ, Beadle BM, Owen J, Movsas B. Surgical patterns of care in operable lung carcinoma treated with radiation. J Thorac Oncol. 2006 Jul; 1(6):526-31. PMID: 17409912.
      View in: PubMed
    205. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul; 4(6):548-82. PMID: 16813724.
      View in: PubMed
    206. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):117-25. PMID: 16765528.
      View in: PubMed
    207. Nelson C, Starkschall G, Chang JY. The potential for dose escalation in lung cancer as a result of systematically reducing margins used to generate planning target volume. Int J Radiat Oncol Biol Phys. 2006 Jun 01; 65(2):573-86. PMID: 16690439.
      View in: PubMed
    208. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, Mohan R, Komaki R, Cox JD. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1087-96. PMID: 16682145.
      View in: PubMed
    209. Chang JY, Zhang X, Komaki R, Cheung R, Fang B. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006 Apr 01; 64(5):1482-94. PMID: 16580499.
      View in: PubMed
    210. Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani J, Phan A, Swisher S, Allen P, Cox JD, Komaki R. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9. PMID: 17409865.
      View in: PubMed
    211. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR, Hong WK, Wu X. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):441-7. PMID: 16342067.
      View in: PubMed
    212. Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol. 2005 Dec; 77(3):247-53. PMID: 16298001.
      View in: PubMed
    213. Zhang X, Cheung RM, Komaki R, Fang B, Chang JY. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6657-68. PMID: 16166445.
      View in: PubMed
    214. Chang JY, Liu HH, Komaki R. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr Oncol Rep. 2005 Jul; 7(4):255-9. PMID: 15946583.
      View in: PubMed
    215. Wang H, Dong L, O'Daniel J, Mohan R, Garden AS, Ang KK, Kuban DA, Bonnen M, Chang JY, Cheung R. Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. Phys Med Biol. 2005 Jun 21; 50(12):2887-905. PMID: 15930609.
      View in: PubMed
    216. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3342-8. PMID: 15867233.
      View in: PubMed
    217. Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8. PMID: 15837739.
      View in: PubMed
    218. Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao Z, Fossella FV, Travis E, Spitz MR. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S92-8. PMID: 16015542.
      View in: PubMed
    219. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64. PMID: 15708243.
      View in: PubMed
    220. Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36. PMID: 15380576.
      View in: PubMed
    221. Chang JY. Telomerase: a potential molecular marker and therapeutic target for cancer. J Surg Oncol. 2004 Jul 15; 87(1):1-3. PMID: 15221912.
      View in: PubMed
    222. Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, Chandra A, Guerrero T, Stevens C, Chang JY, Jeter M, Cox JD, Komaki R, Mohan R, Change JY. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15; 58(4):1258-67. PMID: 15001271.
      View in: PubMed
    223. Yang DJ, Bryant J, Chang JY, Mendez R, Oh CS, Yu DF, Ito M, Azhdarinia A, Kohanim S, Edmund Kim E, Lin E, Podoloff DA. Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex. Anticancer Drugs. 2004 Mar; 15(3):255-63. PMID: 15014359.
      View in: PubMed
    224. Taylor NA, Liao ZX, Cox JD, Stevens C, Roth J, Walsh G, Chang JY, Guerrero T, Jeter M, Putnam J, Fossella FV, Allen P, Komaki R. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys. 2004 Jan 01; 58(1):204-12. PMID: 14697440.
      View in: PubMed
    225. Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D, Walsh G, Guerrero T, Chang J, Bell B, Komaki R, Forster KM. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. 2003 Nov-Dec; 9(6):476-84. PMID: 14740977.
      View in: PubMed
    226. Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, Hung MC. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ther. 1998 Nov; 5(11):1538-44. PMID: 9930307.
      View in: PubMed
    227. Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene. 1997 Feb 06; 14(5):561-8. PMID: 9053854.
      View in: PubMed
    228. Chang JY, Xia W, Shao R, Hung MC. Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Oncogene. 1996 Oct 03; 13(7):1405-12. PMID: 8875978.
      View in: PubMed
    229. Preclinical rationale and clinical considerations for radiotherapy plus immunotherapy going beyond local control. Cancer Journal (United States). 22:130-137.
    230. Improving cardiac dosimetry. Practical Radiation Oncology. 2:41-45.
    231. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation. International Journal of Radiation Oncology Biology Physics. 87:1-2.
    232. Evaluation of the systematic error in using 3D dose calculation in scanning beam proton therapy for lung cancer. Journal of Applied Clinical Medical Physics. 15:47-56.
    233. Intensity-Modulated Radiotherapy, Not 3 Dimensional Conformal, Is the Preferred Technique for Treating Locally Advanced Lung Cancer. Seminars in Radiation Oncology. 25:110-116.
    234. Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy. Advanced Drug Delivery Reviews. 30:219-227.
    235. Erratum. International Journal of Radiation Oncology Biology Physics. 59:921.
    236. Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer. Journal of Thoracic Disease. 6:285-286.
    237. Acquired-resistance of bevacizumab treatment for radiation brain necrosis. Oncotarget. 7:13265-13268.
    238. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients. Annals of Thoracic Surgery.
    239. Oligometastases/oligo-recurrence of lung cancer. Pulmonary Medicine.
    240. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 7:967-980.
    241. Proton therapy for non-small cell lung cancer. Thoracic Cancer. 3:99-108.
    242. Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics.
    243. In regard to Vanderstraeten et al. International Journal of Radiation Oncology Biology Physics. 90:238.
    244. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. Journal of Geriatric Oncology.
    245. Requirements and implementation of a lung sbrt program in a developing country. International Journal of Radiation Oncology Biology Physics. 95:1236-1238.
    246. Immunotherapy and stereotactic ablative radiotherapy (ISABR). Nature Reviews Clinical Oncology.
    247. Stereotactic ablative radiotherapy. Practical Radiation Oncology. 1:38-39.
    248. Is surgery still the optimal treatment for stage I non-small cell lung cancer?. Translational Lung Cancer Research. 5:183-189.
    249. Association between genetic variants in DNA double-strand break repair pathways and risk of radiation therapy-induced pneumonitis and esophagitis in non-small cell lung cancer. Cancers. 8.
    250. Motion-robust intensity-modulated proton therapy for distal esophageal cancer. Medical Physics. 43:1111-1118.
    251. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 7:84688-84694.
    252. Erratum. International Journal of Radiation Oncology Biology Physics. 94:638.
    253. Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs. Tumor Biology. 1-8.
    254. Pleural tumors. 79-93.
    255. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage i peripheral non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics. 93:757-764.
    256. Charged particles in stereotactic radiosurgery. 135-146.
    257. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics. 87:2.
    258. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Scientific Reports. 6.
    259. ACR appropriateness criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer. ONCOLOGY (United States). 28.
    260. Lung Cancer.
    261. In reply to Dr. Bonger et al. International Journal of Radiation Oncology Biology Physics. 82:492.
    262. Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation. Oncotarget. 7:48842-48849.
    263. Comparison of Conformity Index In 3D-CRT, IMRT, and Proton Therapy in Lung Cancer. International Journal of Radiation Oncology Biology Physics. 68:1272.
    264. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology. 1.
    265. MiRNA-related genetic variations associated with radiotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. PLoS One. 11.
    266. Preface. Unknown Journal. xiii.
    267. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics.
    268. Proton Therapy. 338-352.
    269. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Practical Radiation Oncology. 7:63-71.
    270. In vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation. Molecular Therapy - Nucleic Acids. 4.
    271. A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials. Journal of Applied Clinical Medical Physics. 9:110-122.
    272. Proton Therapy. 271-282.
    273. Analysis of risk and predictors of brain radiation necrosis after radiosurgery. Oncotarget. 7:7773-7779.
    274. Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. Journal of Thoracic Disease. 6:348-355.
    275. Stereotactic ablative radiation therapy combined with immunotherapy for solid tumors. Cancer Journal (United States). 22:257-266.
    276. Stereotactic ablative radiotherapy for adrenal gland metastases. Practical Radiation Oncology.
    277. Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-Small Cell Lung Cancer. 379-389.
    278. The abscopal effect of local radiotherapy. Cancer Treatment Reviews. 41:503-510.
    279. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. Journal of Pain and Symptom Management.
    CHANG's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description